In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...
DENVER — Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions in immunocompromised patients, according to results of a phase 3 ...
Herpes simplex virus type 1 (HSV-1) infection dramatically remodels the host cell's nuclear structures. Infection leads to the formation of viral replication compartments and to chromatin ...
Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...
The incidence of neonatal herpes simplex virus (HSV) infections in the UK and Ireland increased dramatically over 15 years, and outcomes remained poor, with mortality and long-term neurologic ...
Inhibiting the herpes simplex virus type 1 viral enzyme uracil-DNA glycosylase reactivates the natural defense protein apolipoprotein B mRNA editing enzyme, catalytic polypeptide-1 (APOBEC1) in the ...
– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...
Researchers found that Herpes simplex virus type 1 reorganizes nuclear speckles, essential sites for RNA processing. Without intact speckles, viral messenger RNAs cannot exit the nucleus, limiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results